Published in TB and Outbreaks Week, February 11th, 2003
"The timely evaluation of new drugs that can be used to shorten tuberculosis (TB) treatment will require surrogate markers for relapse," explained Robert S. Wallis and colleagues at the University of Medicine and Dentistry of New Jersey in Newark, Case Western Reserve University in Cleveland, the University of Arkansas for Medical Sciences in Little Rock, and Universidade Federal do Espiritu Santo in Espiritu Santo, Brazil.
Whole blood bactericidal activity (WBA) is highly useful as a relapse marker, Wallis and...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of TB and Outbreaks Week